Aquestive Therapeutics (Formerly known as MonoSolRx)
1701 County Line Road
Portage
Indiana
46368
United States
Tel: 219-762-3165
Website: http://www.monosol.com/
Email: film@monosol.com
195 articles with Aquestive Therapeutics (Formerly known as MonoSolRx)
-
The current president, CEO and board member, Keith Kendall, is departing Aquestive. He will be replaced by Daniel Barber, its current chief operating officer.
-
Aquestive Therapeutics Announces CEO Transition
5/17/2022
Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced that Keith Kendall, President and Chief Executive Officer and member of the Board of Directors of the Company, is leaving the Company.
-
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
5/10/2022
Aquestive Therapeutics, Inc. announced that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th.
-
Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/3/2022
Aquestive Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent developments in its business.
-
Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET
4/18/2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that it will report results for first quarter ended March 31, 2022.
-
Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital
4/13/2022
Aquestive Therapeutics, Inc. announced it has entered into a common stock purchase agreement for up to $40 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.
-
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
4/12/2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST), today announced positive topline results from Part 2 of the EPIPHAST study for its AQST-109 epinephrine oral film.
-
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
3/17/2022
Aquestive Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions.
-
Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance
3/8/2022
Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent developments in its business.
-
Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China
3/3/2022
Aquestive Therapeutics, Inc. announced the execution of a License, Development and Supply Agreement with Haisco Pharmaceutical Group Co., Ltd. (SZSE : 002653) (“Haisco”), a pharmaceutical company based in the People’s Republic of China (“China”), for Haisco to develop and exclusively commercialize EXSERVAN™ (riluzole oral film) for the treatment of amyotrophic lateral sclerosis (“ALS”) in China.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
2/28/2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, presented a late breaking poster recapping positive topline data from a Phase 1 pharmacokinetic study of AQST-109 epinephrine oral film at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.
-
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
2/25/2022
Aquestive Therapeutics, Inc. today announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film.
-
Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
2/25/2022
Aquestive Therapeutics, Inc. announced the opening of its Investigational New Drug Application from the U.S. Food and Drug Administration for its drug candidate AQST-109 epinephrine oral film.
-
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
2/22/2022
Aquestive Therapeutics, Inc. announced today that it will report results for fourth quarter and year ended December 31, 2021 and provide an update on recent developments in its business after market close on Tuesday, March 8, 2022.
-
Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
1/7/2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th.
-
Although the U.S. FDA largely cleared its calendar ahead of the holidays, it still has a couple open PDUFA dates leading up to January 1, 2022. Here’s a look.
-
Aquestive Therapeutics Added to NASDAQ Biotechnology Index
12/17/2021
Aquestive Therapeutics, Inc. today announced that NASDAQ has added the company to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective December 20, 2021.
-
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
12/13/2021
Aquestive Therapeutics, Inc. today reported that it has received a written response from FDA to its pre-investigational new drug (pre-IND) meeting submission confirming that the development of AQST-109 for the treatment of anaphylaxis under the 505(b)(2) pathway is acceptable.
-
Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
11/17/2021
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.